
FDA approves GSK's unique myelofibrosis treatment Ojjaara
The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (NYSE:GSK) novel treatment, Ojjaara (momelotinib), for adults with intermediate- or high-risk myelofibrosis and...
The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (NYSE:GSK) novel treatment, Ojjaara (momelotinib), for adults with intermediate- or high-risk myelofibrosis and...
Incyte Corp. INCY shares dropped more than 5% premarket on Monday after the U.S. Food and Drug Administration on Friday approved a GSK PLC GSK blood-cancer treatment, Ojjaara, that will...
An analyst from Stifel maintained Incyte (NASDAQ: INCY) at 'hold' with a price target of $76.00 from a prior price target of %currency%%price%. Prior to this rating, Incyte had 10 buy...
An analyst from Truist Securities maintained Incyte (NASDAQ: INCY) at 'buy' with a price target of $91.00 from a prior price target of %currency%%price%. Prior to this rating, Incyte had...
An analyst from BMO Capital maintained Incyte (NASDAQ: INCY) at 'market perform' with a price target of $68.00 from a prior price target of %currency%%price%. Prior to this rating, Incyte...
An analyst from RBC Capital maintained Incyte (NASDAQ: INCY) at 'sector perform' with a price target of $73.00 from a prior price target of %currency%%price%. Prior to this rating, Incyte...
Incyte Corporation's (NASDAQ: INCY) Q2 adjusted EPS reached $0.99, compared to $1.01 posted a year ago. Analysts had estimated $0.87. Q2 revenues increased by 25% Y/Y to $954.61 million,...
Investing.com - Incyte (NASDAQ: INCY) reported second quarter EPS of $0.99, $0.28 better than the analyst estimate of $0.71. Revenue for the quarter came in at $954.61M versus the consensus...
Investing.com - Incyte (NASDAQ: INCY) reported second quarter EPS of $0.99, $0.28 better than the analyst estimate of $0.71. Revenue for the quarter came in at $827M versus the consensus...
Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, and Incyte...
An analyst from Citi initiated coverage of Incyte (NASDAQ: INCY) at 'buy' with a price target of $82.00. Prior to this rating, Incyte had 9 buy ratings, 11 hold ratings, and 0 sell...
Syndax Pharmaceuticals (SNDX) Climbs 14% Following Positive Results form Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease Earlier: Syndax Pharmaceuticals (SNDX) and...
Syndax Pharmaceuticals (Nasdaq: NASDAQ:SNDX) and Incyte (Nasdaq: NASDAQ:INCY) today announced positive topline data from the pivotal AGAVE-201 trial of axatilimab, an anti-CSF-1R...
Incyte (Nasdaq:INCY) today announced positive topline results from its randomized, vehicle-controlled, pivotal Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream...
By Davit KirakosyanInvesting.com -- Here is your Pro Recap of the biggest analyst cuts you may have missed since yesterday.|PacWest Bancorp downgraded to Neutral, shares plunge on potential...
A JMP Securities analyst maintained Incyte (NASDAQ: INCY) at Market Outperform and a price target of $93.00 from a prior price target of %currency%%price%. Prior to this rating, Incyte had...
A Morgan Stanley analyst maintained Incyte (NASDAQ: INCY) at Equalweight and a price target of $74.00 from a prior price target of %currency%%price%. Prior to this rating, Incyte had 10...
An Evercore ISI analyst maintained Incyte (NASDAQ: INCY) at In Line and a price target of $80.00 from a prior price target of %currency%%price%. Prior to this rating, Incyte had 9 buy...
Investing.com - Incyte (NASDAQ: INCY) reported first quarter EPS of $0.37, $0.18 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $808.67M versus the consensus...
Incyte (Nasdaq:NASDAQ:INCY) today announced new data from the Phase 2 SCRATCH-AD trial evaluating the short-term clinical benefits of Opzelura® (ruxolitinib) cream 1.5% to control pruritus...
A Morgan Stanley analyst maintained Incyte (NASDAQ: INCY) at Equalweight and a price target of $77.00 from a prior price target of %currency%%price%. Prior to this rating, Incyte had 9...
A RBC Capital analyst downgraded Incyte (NASDAQ: INCY) from Outperform to Sector Perform with a price target of $79.00 from a prior price target of %currency%%price%. Prior to this rating,...
Incyte (Nasdaq: NASDAQ:INCY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre® (pemigatinib), a selective fibroblast growth factor...
A SVB Leerink analyst upgraded Incyte (NASDAQ: INCY) from Underperform to Market Perform with a price target of $61.00 from a prior price target of %currency%%price%. Prior to this rating,...
Incyte (Nasdaq: NASDAQ:INCY) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for ruxolitinib extended-release (XR) tablets, a JAK1/JAK2...
Incyte (Nasdaq: NASDAQ:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz™ (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed...
Incyte (Nasdaq: NASDAQ:INCY) today announced new 104-week results from the pivotal Phase 3 TRuE-V clinical trial program evaluating Opzelura® (ruxolitinib) cream 1.5% in patients 12 years of...
Incyte (Nasdaq: NASDAQ:INCY) today announced new data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor,...
Incyte (Nasdaq: NASDAQ:INCY) today announced that it will discontinue the Phase 3 LIMBER-304 trial following results of a pre-planned interim analysis conducted by an independent data...
Incyte (Nasdaq:NASDAQ:INCY) today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the...
Incyte (INCY) reported Q4 EPS of $0.62, $0.32 better than the analyst estimate of $0.30. Revenue for the quarter came in at $926.7 million versus the consensus estimate of $878.16...
Investing.com - Incyte (NASDAQ: INCY) reported fourth quarter EPS of $0.62, $0.32 better than the analyst estimate of $0.30. Revenue for the quarter came in at $926.7M versus the consensus...
By Michael Elkins Piper Sandler initiated coverage of Incyte (NASDAQ:INCY) with an Overweight rating and $100.00 price target as analysts see potential growth in the company's venture into...
Investing.com - Incyte (NASDAQ:INCY) reported on Tuesday third quarter {{erl-16360||earnings that beat analysts' forecasts and revenue that fell short of expectations. Incyte announced...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.